Business Wire

Pegasus Digital Mobility Acquisition Corp. Announces Redemption Results and Confirms Voluntary Payment Amount

27.7.2023 16:37:00 EEST | Business Wire | Press release

Share

Pegasus Digital Mobility Acquisition Corp. (NYSE: PGSS.U) (the "Company"), a special purpose acquisition company founded by Pegasus Digital Mobility Sponsor (the "Sponsor") and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganisation or similar business combination with one or more businesses or assets (a "Business Combination"), today announced that holders of 2,195,855 of the Company's Class A ordinary shares exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account in connection with the announcement of the further extension of the period of time the Company has to consummate its proposed Business Combination with Gebr. SCHMID GmbH (the "SCHMID Group") to December 31, 2023. As a result, approximately $53.7 million will be remaining in the Company's trust account. Following the redemption, the Company's remaining number of issued and outstanding Class A ordinary shares was 5,003,218.

Commencing on August 1, 2023 and paid on the first day of each month thereafter until the earliest of (i) the date on which the Company consummates a Business Combination or (ii) December 31, 2023, the Sponsor will deposit $150,096.54 per month into the Company's trust account, representing $0.03 (three U.S. cents) per Class A ordinary share then in issue. The contribution amount shall be made available and paid on a monthly basis after the issuance of a non-convertible unsecured promissory note from the Company to the Sponsor in connection therewith. Should the Company's Board determine that it will not be able to consummate the initial Business Combination by December 31, 2023 and that the Company shall instead liquidate, the Sponsor's obligation to continue to make such contributions shall immediately cease. If the Board determines that more time is needed to consummate the initial Business Combination, a shareholders' vote in an extraordinary general meeting will be required to change the second amended and restated memorandum and articles of association of the Company.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements involve predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to certain risks and uncertainties, including but not limited to:

  • the occurrence of any event, change or other circumstances that could give rise to the termination of the proposed Business Combination with the SCHMID Group;
  • the outcome of any legal proceedings that may be instituted against the Company, the SCHMID Group, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto;
  • the inability to complete the Business Combination with the SCHMID Group due to the failure to obtain approval of the shareholders of the Company or to satisfy other conditions to closing;
  • changes to the proposed structure of the Business Combination with the SCHMID Group that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination;
  • the ability to meet stock exchange listing standards following the consummation of the Business Combination with the SCHMID Group;
  • the risk that the Business Combination disrupts current plans and operations of the Company or the SCHMID Group as a result of the announcement and consummation of the Business Combination with the SCHMID Group;
  • the ability to recognise the anticipated benefits of the Business Combination with the SCHMID Group, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees;
  • costs related to the Business Combination with the SCHMID Group;
  • changes in applicable laws or regulations and delays in obtaining, adverse conditions contained in, or the inability to obtain regulatory approvals required to complete the Business Combination with the SCHMID Group;
  • the possibility that the Company, the SCHMID Group or the combined company may be adversely affected by other economic, business, and/or competitive factors;
  • the estimates of expenses and profitability and underlying assumptions with respect to shareholder redemptions and purchase price and other adjustments; and
  • other risks and uncertainties set forth in the section entitled "Risk Factors" in the Company's prospectus on Form S-1 approved by the SEC.

The foregoing list of factors is not exhaustive. The forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the SCHMID Group and the Company assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Copies of the Company's registration statement are available on the SEC’s website, www.sec.gov.

Additional Information and Where to Find It

INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ ANY DOCUMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of any documents (including any amendments or supplements thereto) filed with the SEC through the website maintained by the SEC at www.sec.gov or by directing a request to investor-relations@pegasusdm.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pegasus Contact Information
Investor Relations
investor-relations@pegasusdm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AV Access Presents eShare W90: A 4K Wireless Conferencing System for Smarter Hybrid Meetings at ISE 2026 in Barcelona28.1.2026 10:00:00 EET | Press release

AV Access proudly announces its participation in ISE 2026, one of the world’s leading AV and systems integration exhibitions. From February 3-6 at the Fira de Barcelona, Gran Via, the company will showcase its latest solutions designed to improve collaboration, enhance entertainment, and boost workplace productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128178621/en/ The eShare W90 wireless presentation and conferencing system makes hybrid meetings more secure, more collaborative, and far easier to manage. At Booth 1F110, AV Access will highlight its flagship innovations, including the eShare W90 wireless conferencing system, the plug-and-play 4KIP200 HDMI over IP solution, and the complete iDock series of KVM docking stations—demonstrating its dedication to versatile, high-performance AV technology. Stream, Charge and Share with a Single USB-C Cable At the heart of the booth is the eShare W90 wireless presentat

SES Extends EGNOS GEO-1 Satellite Service to Power Precise Navigation Across Europe28.1.2026 09:50:00 EET | Press release

SES, a leading space solutions company, and the European Union Agency for the Space Programme (EUSPA) today announced an extension of the European Geostationary Navigation Overlay Service (EGNOS) GEO-1 satellite service agreement through 2030, with an option to extend until 2032, helping maintain high-precision navigation services for aviation and other critical users across Europe. By improving the accuracy and integrity of satellite positioning signals, EGNOS supports aircraft in landing in low-visibility conditions, as well as planning more efficient routes, reducing fuel burn and CO₂ emissions. At the core of the EGNOS service is Europe’s regional Satellite-Based Augmentation System (SBAS) that improves the accuracy and reliability of Global Navigation Satellite System (GNSS) signals, such as GPS. Beyond aviation, EGNOS supports maritime navigation and precision-driven agriculture, contributing to efficient operations and sustainability by reducing fuel consumption and emissions. U

LTTS Secures Strategic Engineering and R&D Agreement from Global Automotive OEM28.1.2026 09:30:00 EET | Press release

L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, announced that it has secured a significant multi-year engagement in its Mobility segment from a leading automotive OEM. The strategic win further strengthens LTTS’ long-standing partnership with the premium automotive manufacturer and underscores its growing role in supporting next-generation mobility engineering. The engagement encompasses advanced software, connectivity and digital engineering services across multiple vehicle technology domains. LTTS will draw on its global engineering expertise, strong domain knowledge and proven delivery frameworks to support the customer’s evolving product and technology roadmap. This win reinforces LTTS’ comprehensive mobility engineering capabilities, spanning embedded systems, digital platforms, verification and validation, cloud integration, cybersecurity, and cross-disciplinary software–mechanical engineering. LTTS’ investments in sta

SFI Health™ EMEA Announces the Launch in Poland of Equazen ® Forte, Marking a New Chapter in Cognitive Support for Young Adults and Adults28.1.2026 09:00:00 EET | Press release

SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, today is pleased to announce the launch of Equazen® Forte in Poland, a new concentrated omega 3 product formulation to be added to the Equazen® range designed to support the normal cognitive performance for young adults and adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127646023/en/ Equazen® Forte: a key milestone in the brand’s long-term development strategy. Equazen® Forte represents a key milestone in the brand’s long-term development strategy. Traditionally recognized as a pediatric brain health expert, Equazen® is now evolving to support consumers across different life stages, addressing changing cognitive demands from adolescence into adulthood. Equazen® Forte builds on more than 25 years of Equazen® heritage and scientific expertise. Like the rest of the Equazen® range, it features the brand’s unique and clinically

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 08:07:00 EET | Press release

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye